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Clinical Implications: Patients reporting penicillin allergy believe their allergy to be permanent, would 53 
take penicillins if tested negative, but are rarely ferred for penicillin testing, leading to differential 54 
antibiotic utilization. 55 
 56 
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  58 
  59 
Although 8-20% of patients are reported to carry a penicillin allergy label (PAL), more than 95% of these 60 
individuals will be negative on standardized penicillin allergy (PA) testing1-3. Patients with a PAL are 61 
subject to adverse health outcomes, including increased nosocomial infections, surgical site infections, 62 
prolonged time to administration of emergent antibio cs, prolonged hospitalizations, and hospital 63 
readmissions4-6. PA testing has been shown to be safe, facilitates ntibiotic stewardship, and data suggests 64 
it is likely to be cost effective 1,7,8. While much is published regarding the worse outcomes of a PAL and 65 
approaches to remove a PAL9, little is known about PA patients’ willingness to undergo PA testing. 66 
Therefore, we conducted the “Readiness for PENicillin allergy testing: Perception of Allergy Label 67 
(PEN-PAL)” survey to ascertain beliefs, perceptions, and experiences of a current self-reported PA 68 
patient population and to identify potential barriers to testing. 69 
 70 
A survey (Figure E1 in the Online Repository) was created using REDCap (Research Electronic Data71 
Capture), an established secure web-based application for creating and managing online surveys and 72 
databases. Of note, the only mandatory question was whether the patient reported either a current 73 
penicillin allergy, reported a historical penicillin allergy which was removed, or reported no penicillin 74 
allergy. The participants were free to omit answers to all other questions if they did not recall the answer 75 
or if they chose not to answer, and thus, the denominator of responses varied slightly by question. 76 
An email with the survey was sent to 18,943 adult patients (>18 years of age) pre-consented to receive 77 





with three reminder emails, from late October 2019 to early December 2019. Additional details 79 
regarding REDCap and MRAV can be found in the EMethods in the Online Repository.  80 
 81 
For continuous variables, median and interquartile range were calculated.  Statistical comparisons were 82 
performed between the three penicillin allergy status groups. For categorical variables, Fisher’s exact test 83 
or Pearson’s chi-squared statistic were used.  Wilcoxon rank-sum test was used to compare continuous 84 
variables. Statistical analysis was performed using Stata 15.0. 85 
 86 
18,943 eligible participants of MRAV, 5284(28%) completed the survey.  1047(20%) reported a current 87 
PA, 4091(77%) reported no PA, and 146(3%) reported a historical PA which was removed. Participants 88 
reporting a current PA were more likely to be female (Pearson, P<0.005) (Table 1).  89 
 90 
Patients reporting a current PAL experienced their index reaction at a median age of 16 [IQR 6-30] with 91 
most reactions occurring >10 years ago (915/1040, 88%). The three most common types of reactions were 92 
rash only (510/1037, 49%), an unknown reaction (141/ 037, 14%), or “anaphylaxis” (139/1037, 13%), 93 
and all reactions recalled are detailed in Table E1 in the Online Repository. Of the 116/998(12%) who 94 
endorsed receiving epinephrine, 77(66%) recalled th index reaction of “anaphylaxis” and 39(34%) 95 
received epinephrine but didn’t recall the index reaction of “anaphylaxis.” Following the index reaction, 96 
of those who recalled their highest level of care required (805/1034, 78%), most required only an 97 
outpatient visit, phone call, or self-discontinued penicillin (612/805, 76%), while few utilized the 98 
emergency department (106/805, 13%), inpatient floor (62/805, 8%), or the intensive care unit (17/805, 99 
2%).  100 
 101 
Antibiotic utilization differed among those reporting a current PA and the other groups (Figure 1). 102 
Compared to no reported PA, participants reporting a current PA less frequently recalled receiving 103 





amoxicillin/clavulanate** (12% vs 46%), and cephalexin* (40% vs 45%), and more frequently recalled 105 
receiving fluoroquinolones** (11% vs 7%), macrolides** (15% vs 6%), tetracyclines** (8% vs 4%), 106 
clindamycin** (6% vs 1%), sulfa antimicrobials* (6% vs. 4%), and vancomycin* (2% vs 1%) (Pearson 107 
chi-squared *P<0.05, **P<0.005).  Compared to participants reporting a historical PA which was 108 
removed, participants reporting a PA less frequently recalled receiving penicillin** (subsequent to index 109 
reaction) (11% vs 47%), amoxicillin** (24% vs 63%), and amoxicillin/clavulanate** (12% vs 35%), and 110 
more frequently recalled receiving clindamycin* (11% vs 6%), tetracyclines* (8% vs 2%), and 111 
macrolides* (15% vs 8%) (Fisher’s exact test *P<0.05, **P<0.005) (Figure 1). Furthermore, 112 
198/1040(19%) with a PAL had taken and tolerated a penicillin, but continued to self-report their PAL.  113 
 114 
Participants reporting a current PA often discussed th ir PA with a primary care provider (639/1035, 115 
61%), but that conversation rarely comprised of the negative consequences of a PA (73/1040, 7%), and 116 
the minority were offered referral to an allergist for PA testing (38/1040, 4%). Regarding surgeries in PA 117 
patients, 869/1039(81%) reported both a PA and a surgery since their index reaction, and majority of 118 
these (747/861, 87%) had a pre-operative discussion of their PA with a provider. The minority of these 119 
participants perceived their PA had an adverse effect on their medical care (167/1040, 16%).  Most 120 
(799/989, 81%) believed their PA to be permanent, and many believed it “likely” or “very likely” to react 121 
to penicillin today (397/1039, 38%). Despite this, a high proportion (813/1016, 80%) would take 122 
penicillin for an indicated cause if an allergist tested them and found it to be safe.  Overall, 561/1024 123 
(55%) were interested in PA testing.  124 
 125 
This survey is the first which attempts to capture a large population-based sample of attitudes and 126 
experiences of a current reported PA patient, and while the survey link was only sent to those accessing 127 
care at a tertiary medical center, we believe that the conclusions are generalizable to a population level. 128 
Limitations of the study which we do not believe will s gnificantly change conclusions are that many of 129 





the participants whether they had other antibiotic allergies, which may independently alter the antibio cs 131 
received. 132 
 133 
We identified educational points for both patients and providers.  Notably, >80% of those with a current 134 
PA perceived their PA as permanent. However, if the reported histories of rash only, “my family member 135 
told me I’m allergic but I don’t recall,” gastrointestinal distress, unknown history, and family history f 136 
penicillin allergy were applied to a recently validted penicillin allergy risk stratification scheme9,10, 71% 137 
of our PA participants’ reported histories would be categorized as low risk, and thus likely to tolerat   138 
single-dose amoxicillin oral challenge today.  Most (561/1024, 55%) with a current PAL were interested 139 
in PA testing, and the majority (813/1016, 80%) indicated they would take a penicillin if testing was 140 
negative.  Despite this, primary care doctors rarely r ferred our participants for PA testing (38/1040, %).  141 
 142 
Self-reported antibiotic utilization was different between those with and without a current PAL.  PAL 143 
participants recalled significantly fewer β-lactam prescriptions and increased prescriptions of antibiotics 144 
associated with potentially reduced treatment efficacy. Those with a current PAL also recalled fewer β-145 
lactam prescriptions than those with a historical PAL which was removed, highlighting the importance of 146 
PAL testing in guiding antibiotic prescribing patterns.  147 
 148 
PAL patients believed their PAL to be permanent and several retained a PAL despite proven tolerance. 149 
Although they expressed interest in formal allergy assessment, and most would take penicillin if tested 150 
negative, they were rarely referred, leading to differential antibiotic utilization in favor of broader 151 
spectrum and potentially less effective therapy. 152 
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Figure 1: Reported antibiotic utilization, by penicillin allergy status. A) Participants reporting a 186 
current PA less frequently reported utilization of penicillin** (after index reaction, when applicable), 187 
amoxicillin**, amoxicillin/clavulanate**, and cephalexin*. B) Participants reporting a current PA more 188 
frequently reported utilization of fluoroquinolones**, macrolides**, tetracyclines**, clindamycin**, sulfa 189 





Table 1: Demographics of PEN-PAL Survey Participants 195 





Allergy (n= 146) 
P value 
Median Age [IQR] 62 [51-70] 61 [51-69] 64 [51-71] NS 
Gender No. (%)     
   Male 1599 (39) 275 (26) 45 (31) <0.005 
   Female 2464 (60) 769 (73) 99 (68)  
   Other 2 (0) 0 (0) 1 (1)  
   Declined to answer 26 (1) 3 (0) 1 (1)  
Race No. (%)     
   White 3720 (92) 972 (93) 136 (93) NS 
   African American 167 (4) 44 (4) 3 (2)  
   Other 177 (4) 26 (2) 7 (5)  



























































ETable 1: Index reactions recalled by those reporting a penicillin allergy (n= 1037) 1 
Reaction Number (%) 
Rash only 510 (49) 
“A family member told 
me; I don’t remember” 
141 (14) 
Anaphylaxis 139 (13) 
Swelling 68 (7) 
GI Distress 47 (5) 
Unknown 34 (3) 
Hives 33 (3) 
Family history of 
penicillin allergy 
5 (0.5%) 




Online Repository  1 
EMethods 2 
REDCap  3 
Study data were collected and managed using REDCap electronic data capture tools hosted at Vanderbilt 4 
University Medical CenterE1,E 2. REDCap (Research Electronic Data Capture) is a secure, web-based 5 
software platform designed to support data capture for research studies, providing 1) an intuitive interface 6 
for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) 7 
automated export procedures for seamless data downloads to common statistical packages; and 4) 8 
procedures for data integration and interoperability w h external sources.    9 
  10 
MyResearch at Vanderbilt  11 
MyResearch at Vanderbilt (MRAV) is a participant repository recruitment tool available to Vanderbilt 12 
researchers that reaches over 18,000 My Health at Vanderbilt users that have previously confirmed they 13 
would like to be contacted directly for research. Tis repository provides investigators a forum for 14 
advertising for volunteers for a specific study. Email notifications are limited to IRB approved langua e, 15 
describe study specifics and provide contact information. To utilize this initiative, investigators complete 16 
a MyResearch Access Request that is reviewed to ensure the recruitment tool and requested number of 17 
contacts are appropriate.  18 
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EFigure 1:  PENPal Survey Questions 26 
EFigure 1:  PENPal Survey Questions 
1. Sole mandatory question: Do you have a penicillin allergy? 
a. Yes 
b. No 
c. I had a penicillin allergy, but it has since been disproven 












i. List other Race/Ethnicity 
5. Do you recall needing antibiotics for any reason in your lifetime? 
a. Yes 
b. No 
6. Which antibiotics have you taken without issue in your lifetime? Choose all that apply, only 
choose if you are confident 
a. I have confidently taken none of these specifically listed here 
b. Penicillin 
c. Amoxicillin (Amoxil) 
d. Amoxicillin/Clavulanic acid (Augmentin) 
e. Cephalexin (Keflex) 
f. Ceftriaxone (Rocephin) 
g. I have taken an antibiotic not on this list 
i. Which other antibiotics not listed in the previous question have you taken 
without issue in your lifetime? 
h. Unsure 




8. (Answered by those reporting to be female and penicillin allergic only) Do you perceive 
your penicillin allergy affected your pregnancy, deliv ry, or time while nursing/breastfeeding 
in any way? 
a. Yes 
b. No 
c. I became allergic to penicillin after my last pregnancy 
i. Please list how you perceive your penicillin allergy affected your pregnancy, 
delivery, or time while nursing/breastfeeding 
9. (Answered by those reporting to be female only) Did you require antibiotics while 
pregnant, during delivery, or when you were nursing/breastfeeding? 
a. Yes 
b. No 
i. Please list the antibiotics you confidently remember taking while pregnant, 
during delivery, or when you may have been nursing/breastfeeding 
Remainder of questions answered by those reporting to be currently penicillin allergic only 
10. How many years ago did you acquire your penicillin a lergy? 
a. Less than one year ago 
b. Greater than one, but less than five years ago 
c. Greater than five, but less than ten years ago 
d. Greater than 10 years ago 
e. I did not personally have a reaction to penicillin 
f. Not sure 
11. Around what age did you acquire your penicillin allergy? (List age) 
12. What was your reaction to penicillin? 
a. Rash only 
b. Anaphylaxis 
c. Gastrointestinal distress only 
d. My family member told me I’m allergic. I do not rember the reaction 
e. I avoid penicillin because of a family member who did not tolerate penicillin 
f. Unknown 
g. Other 
i. Please list other reaction 
13. During the event leading to your penicillin allergy, what was the most involved level of care 
you required? 
a. It was stopped without talking to a provider 
b. A health care practitioner recommended stopping it over the phone 
c. Urgent Care/Primary Care doctor visit 
d. Emergency Room 
e. Inpatient hospitalization, not requiring the intensive care unit 
f. Inpatient hospitalization, requiring the intensive care unit 
g. The penicillin allergy label was acquired based on a reaction that occurred with a 
relative 
h. Do not remember 




15. If you were prescribed penicillin today, how likely would it be for you to have a reaction to 
it? 




e. Very unlikely 




17. Did you provider discuss your penicillin allergy prior to prescribing those antibiotics 
a. Yes 
b. No 
18. Which antibiotics have you taken without issue SINCE ACQUIRING YOUR PENICIILIN 
ALLERGY? Choose all that apply, only choose if you are confident. 
a. I have confidently taken none of these specifically listed here 
b. Penicillin 
c. Amoxicillin (Amoxil) 
d. Amoxicillin/Clavulanic acid (Augmentin) 
e. Cephalexin (Keflex) 
f. Ceftriaxone (Rocephin) 
g. I have taken an antibiotic not on this list 
i. Which other antibiotics not listed in the previous question have you taken 
without issue SINCE ACQUIRING YOUR PENICILLIN ALLERGY? 
h. Unsure 
19. Has your primary care provider talked to you about your penicillin allergy? 
a. Yes 
b. No 
20. Has your primary care provider offered to refer youf r penicillin allergy testing? 
a. Yes 
b. No 




22. Have you had a surgery since acquiring your penicilli  a lergy? 
a. Yes 
b. No 




24. Do you believe that your penicillin allergy is permanent? 
a. Yes 
b. No 
25. If your regular healthcare provider wanted to prescribe penicillin, and an allergist tested you 
and found it to be safe, would you take it? 
a. Yes 
b. No 
i. If not, please list why 
26. Would you be interested in being referred for penicillin allergy evaluation? 
a. Yes 
b. No 
